These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9035045)

  • 1. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug--proposals for designing non-clinical and clinical studies--is the non-clinical study useful?
    Ozawa N
    J Toxicol Sci; 1996 Dec; 21(5):323-9. PubMed ID: 9035045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
    Sugiyama Y; Iwatsubo T; Ueda K; Ito K
    J Toxicol Sci; 1996 Dec; 21(5):309-16. PubMed ID: 9035043
    [No Abstract]   [Full Text] [Related]  

  • 3. Basic strategy for avoiding drug interaction during stage of drug development; proposals relative to planning of non-clinical and clinical studies and how clinical trials should be planned.
    Horie T; Nakata H; Kusube K
    J Toxicol Sci; 1996 Dec; 21(5):331-9. PubMed ID: 9035046
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 5. Strategic proposals to avoid toxic drug interactions during new drug development: molecular toxicology proposals.
    Kamataki T; Yokoi T; Yamayoshi Y; Nakamura K; Kushida H; Fujita K; Mitsuhashi H; Ueno T
    J Toxicol Sci; 1996 Dec; 21(5):305-8. PubMed ID: 9035042
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetic drug interactions in liver disease: An update.
    Palatini P; De Martin S
    World J Gastroenterol; 2016 Jan; 22(3):1260-78. PubMed ID: 26811663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic screening for pharmacokinetic interactions during drug development.
    Fuhr U; Weiss M; Kroemer HK; Neugebauer G; Rameis H; Weber W; Woodcock BG
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):139-51. PubMed ID: 8861732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
    Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of drugs after marketing.
    J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategic proposals for predicting drug-drug interactions during new drug development: based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs.
    Watabe T
    J Toxicol Sci; 1996 Dec; 21(5):299-300. PubMed ID: 9035040
    [No Abstract]   [Full Text] [Related]  

  • 11. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises.
    Corrigan OP
    Soc Sci Med; 2002 Aug; 55(3):497-507. PubMed ID: 12144155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proposal for avoiding toxic interactions of a drug under development to estimate inhibitory ability on the drug metabolizing enzymes in human liver.
    Noguchi H
    J Toxicol Sci; 1996 Dec; 21(5):317-21. PubMed ID: 9035044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan.
    Mori J; Tanimoto T; Miura Y; Kami M
    Jpn J Clin Oncol; 2015 Jun; 45(6):588-94. PubMed ID: 25759486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery.
    Lin J; Sahakian DC; de Morais SM; Xu JJ; Polzer RJ; Winter SM
    Curr Top Med Chem; 2003; 3(10):1125-54. PubMed ID: 12769713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing surveillance of adverse drug reactions in general practice. I: search for new methods.
    Inman WH
    Br Med J (Clin Res Ed); 1981 Apr; 282(6270):1131-2. PubMed ID: 6786470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-herb interactions: eliminating toxicity with hard drug design.
    Yang XX; Hu ZP; Duan W; Zhu YZ; Zhou SF
    Curr Pharm Des; 2006; 12(35):4649-64. PubMed ID: 17168768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.
    Showalter HD; Denny WA
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S3-17. PubMed ID: 18762151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A problem-oriented approach to safety issues in drug development and beyond.
    Haas JF
    Drug Saf; 2004; 27(8):555-67. PubMed ID: 15154827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.
    Zhou SF
    Curr Pharm Des; 2008; 14(10):990-1000. PubMed ID: 18473851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.